George Somlo Selected Research

Triple Negative Breast Neoplasms

1/2022	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
1/2021	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
1/2021	Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
4/2019	Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
6/2017	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
9/2015	Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
2/2015	Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
1/2015	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Somlo Research Topics

Disease

66	Neoplasms (Cancer) 01/2022 - 11/2002
63	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2002
24	Multiple Myeloma 01/2022 - 11/2003
8	Triple Negative Breast Neoplasms 01/2022 - 01/2015
6	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2007
5	Pathologic Complete Response 01/2022 - 06/2013
5	Disease Progression 01/2019 - 12/2011
4	Circulating Neoplastic Cells 01/2022 - 09/2009
4	Leukemia 12/2019 - 02/2003
4	Peripheral Nervous System Diseases (PNS Diseases) 10/2012 - 01/2004
3	Nausea 08/2017 - 02/2007
3	Thrombocytopenia (Thrombopenia) 08/2017 - 02/2003
3	Lymphoma (Lymphomas) 10/2015 - 05/2005
3	Infections 01/2015 - 07/2006
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2013 - 02/2003
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2013 - 05/2008
3	Sarcoma (Soft Tissue Sarcoma) 08/2010 - 09/2004
2	Carcinogenesis 01/2020 - 01/2013
2	Inflammatory Breast Neoplasms 01/2018 - 05/2004
2	Fatigue 08/2015 - 09/2007
2	Bronchiolitis Obliterans Syndrome 08/2014 - 04/2005
2	Lung Neoplasms (Lung Cancer) 01/2013 - 09/2009
2	Vomiting 07/2012 - 02/2007

Drug/Important Bio-Agent (IBA)

10	Estrogen ReceptorsIBA 12/2021 - 05/2004
9	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2004
9	Hormones (Hormone)IBA 01/2022 - 04/2013
9	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2008
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2004
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2004
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2005
7	MicroRNAs (MicroRNA)IBA 02/2016 - 08/2009
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2004
6	Bortezomib (Velcade)FDA Link 01/2019 - 01/2009
6	Trastuzumab (Herceptin)FDA Link 01/2016 - 03/2006
5	Bevacizumab (Avastin)FDA Link 01/2022 - 08/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 11/2021 - 03/2012
5	Gemcitabine FDA Link 01/2010 - 11/2002
4	RNA (Ribonucleic Acid)IBA 12/2021 - 03/2012
4	Lenalidomide (CC 5013)FDA Link 11/2021 - 02/2013
4	130-nm albumin-bound paclitaxelIBA 01/2021 - 01/2015
4	PlatinumIBA 01/2021 - 11/2002
4	Interleukin-6 (Interleukin 6)IBA 10/2017 - 12/2010
3	Messenger RNA (mRNA)IBA 01/2022 - 01/2005
3	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 01/2009
3	Estrogens (Estrogen)FDA Link 12/2021 - 07/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 01/2018
3	Pharmaceutical PreparationsIBA 04/2019 - 01/2013
3	human ERBB2 proteinIBA 01/2019 - 08/2010
3	Biological ProductsIBA 06/2018 - 08/2010
3	Docetaxel (Taxotere)FDA Link 01/2018 - 12/2003
3	Monoclonal AntibodiesIBA 11/2015 - 12/2009
3	CytokinesIBA 08/2015 - 06/2012
3	Progesterone Receptors (Progesterone Receptor)IBA 04/2014 - 05/2004
3	ErbB Receptors (EGF Receptor)IBA 02/2014 - 09/2009
3	carfilzomibIBA 10/2012 - 06/2011
3	Thalidomide (Thalomid)FDA Link 03/2012 - 09/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2009 - 01/2005
3	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 01/2009 - 01/2005
2	Everolimus FDA Link 01/2022 - 08/2018
2	pomalidomideIBA 11/2021 - 07/2018
2	LeptinIBA 01/2020 - 01/2018
2	Phosphotransferases (Kinase)IBA 04/2019 - 12/2010
2	palbociclibIBA 04/2019 - 06/2018
2	sapanisertibIBA 04/2019 - 08/2018
2	trans-crotonin (CTN)IBA 01/2019 - 12/2011
2	Aromatase InhibitorsIBA 08/2018 - 03/2006
2	Vorinostat FDA Link 01/2018 - 11/2008
2	fibrin fragment D (D-dimer)IBA 10/2017 - 08/2017
2	Blood Coagulation Factors (Coagulation Factor)IBA 10/2017 - 08/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2017 - 11/2014
2	veliparibIBA 08/2017 - 11/2014
2	Phenobarbital (Luminal)FDA Link 01/2017 - 01/2013
2	Filgrastim (Neupogen)FDA Link 10/2015 - 01/2014
2	AnthracyclinesIBA 02/2015 - 07/2012
2	taxaneIBA 02/2015 - 01/2014
2	DNA (Deoxyribonucleic Acid)IBA 11/2014 - 09/2009
2	Vinorelbine (Navelbine)FDA LinkGeneric 04/2014 - 01/2014
2	Dasatinib (BMS 354825)FDA Link 06/2013 - 04/2013
2	Capecitabine (Xeloda)FDA Link 04/2013 - 11/2009
2	Proteasome InhibitorsIBA 10/2012 - 10/2012
2	Imatinib Mesylate (Gleevec)FDA Link 08/2010 - 02/2010
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 11/2009 - 05/2008
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2009 - 03/2007

Therapy/Procedure

40	Therapeutics 01/2022 - 11/2003
29	Drug Therapy (Chemotherapy) 01/2019 - 06/2003
11	Neoadjuvant Therapy 01/2022 - 01/2012
9	Cell Transplantation 12/2019 - 11/2003
8	Stem Cell Transplantation 08/2014 - 02/2003
6	Adjuvant Chemotherapy 12/2018 - 09/2009
6	Radiotherapy 01/2017 - 05/2004
4	Transplantation 01/2019 - 06/2003
3	Autologous Transplantation 01/2022 - 08/2009
3	Biological Therapy 03/2016 - 04/2014
3	Salvage Therapy 01/2013 - 04/2005
3	Homologous Transplantation 01/2013 - 02/2003
2	Aftercare (After-Treatment) 01/2018 - 09/2009
2	Immunotherapy 01/2018 - 02/2003
2	Segmental Mastectomy (Lumpectomy) 01/2016 - 09/2015
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 03/2012 - 11/2005
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2011 - 01/2009